Diseases
Research at the National Institute of Neuroscience in Tokyo, Japan, has shed new light on the role of thyroid hormone receptor beta (TR-b) signaling in autoimmune disease. Investigators found that TR-b signaling controls the function of pathogenic T helper (Th) cells, which are involved in the development of autoimmune diseases
Diseases
Research has documented a case of statin-associated necrotizing autoimmune myopathy (NAM) unmasked by statin re-exposure in a 65-year-old man. The patient had experienced worsening, painless proximal muscle weakness and significant creatine kinase (CK) elevation shortly after resuming statin therapy following a temporary discontinuation. Diagnostic workup revealed positive 3-hydroxy-3-methylglutaryl-CoA reductase antibodies
Diseases
Researchers at the University of Florence have conducted a systematic review to better understand neuropathic pain associated with Contactin-associated protein-like 2 (CASPR2) antibodies. The study found that 7.4% of patients with CASPR2 antibody disease spectrum presented with isolated neuropathic pain, which was typically severe and presented as distal burning
Diseases
Recent research at the University of Jinan in Shenzhen, People's Republic of China, has shed new light on the complex pathogenesis of diabetic kidney disease (DKD). The study examined the role of microRNAs (miRNAs) in the development of DKD, focusing on the methylation modifications of miRNAs in peripheral
Diseases
South Korean biotech firm AppClone has achieved a significant milestone with its next-generation CAR-T therapy, 'Nespeseal (AT101)', receiving designation as a development-stage orphan drug by the Ministry of Food and Drug Safety. This designation provides AppClone with various benefits, including extended marketing authorization, simplified data submission, and exclusive
Diseases
Researchers from the University of Lubeck have published a study on the potential of epigenetic mechanisms as mediators of genetic and environmental influences in Alzheimer's disease. The study focuses on blood-based DNA methylation signatures as minimally invasive peripheral biomarkers for the disease. The investigators found associations between blood
Diseases
Research presented by Lily Zhong and colleagues at the Veterans Affairs Medical Center in San Francisco, California, has shed new light on the mechanisms underlying Alzheimer's disease (AD) in women. According to the researchers, approximately 50 million people worldwide are affected by AD, with women making up two-thirds
Diseases
A systematic review and meta-analysis published in the Annals of Medicine & Surgery has found that the Zephyr valve treatment may improve lung function, exercise capacity, and quality of life for patients suffering from severe emphysema. The study, conducted by a team of researchers from the Department of Medicine at
Diseases
Research from AstraZeneca has shed light on the pathogenic roles of Th17 cells in autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, and psoriasis. Studies have shown that targeting Th17 cell-related cytokines, such as IL-17 and IL-23, can provide clinical benefits in treating inflammatory diseases. The research highlights the
Diseases
Research at the Mayo Clinic Alix School of Medicine has shed light on the disparities in healthy longevity across different world regions. By analyzing data from the World Health Organization's Global Health Observatory, researchers uncovered a significant gap between the lifespan and healthspan of individuals in various regions.
Diseases
Research from NHS Grampian in the United Kingdom has uncovered significant evidence that exercise can improve Non-Alcoholic Fatty Liver Disease (NAFLD), a condition affecting 5% of the global population, without dependence on weight loss. Epidemiological studies have shown a strong association between reduced physical activity and NAFLD, while exercise has
Diseases
The U.S. Food and Drug Administration (FDA) has approved a subcutaneous formulation of Leqembi (lecanemab), branded as Leqembi Iqlik, for weekly maintenance dosing following an 18-month IV initiation phase. This breakthrough approval opens the door for faster and simpler drug delivery and paves the way for combination therapies, a
